Marta García-Fiñana
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Marta García-Fiñana has a total of 167 co-authors. Here are the top co-authors by number of shared publications:
- Iain Buchan
University of Liverpool
9 shared publications - David Michael Hughes
Department of Health Data Science, University of Liverpool, Liverpool, UK
5 shared publications Christopher P. Cheyne
Civic Health Innovation Labs, University of Liverpool, Liverpool Science Park, 131 Mount Pleasant, Liverpool L35TF, UK; Department of Health Data Science, University of Liverpool, Waterhouse Building, Block B, Brownlow Street, Liverpool L693GF, UK
4 shared publicationsDavid M. Hughes
Department of Health Data Science, Institute of Population Health University of Liverpool Liverpool UK
4 shared publicationsNeil Roberts
Clinical Research Imaging Centre (CRIC), School of Clinical Sciences, University of Edinburgh, UK
4 shared publications- Christopher P. Cheyne
Dept. Health Data Science, University of Liverpool
3 shared publications
Latest Publications
- Open Access
- 1 July 2026
- Published by SAGE Publications in Journal of the Royal Society of Medicine
- Vol. 119 (7) , 190-204
Industrial action and emergency department attendances in England, 2022–2024: a retrospective multicentre causal mediation analysis
Objectives: Between December 2022 and July 2024, the English National Health Service (NHS) experienced 27 periods of industrial action spanning 78 days, involving hospital and ambulance staff. We examined the direct and indirect impacts of these strikes on emergency department (ED) performance Design: A retrospective causal mediation analysis. Effects were estimated using mixed effects accelerated failure time, linear and generalised linear regression models with patient- and hospital-level covariates within a causal mediation framework. Setting: 20 major (Type 1) EDs in England with high-quality linkage across ED, inpatient, and imaging data. Participants: Patients attending these EDs between August 2022 and July 2024. Main outcome measures: A patient’s time in ED analysed in relation to strike activity at the mid-point of attendance by one or more staff groups: (1) resident/junior doctors, (2) consultants, (3) both resident and consultant doctors, (4) paramedics and (5) nurses. Results: Average duration of ED attendances reduced on days affected by residents’ strikes (-12.6%, 95% CI -10.4% to -14.8%), consultant strikes (-5.6%, 95% CI -2.7% to -8.4%), paramedic strikes (-4.5%, 95% CI -2.0% to -6.8%), but increased when residents and consultants were on strike simultaneously (+7.2%, 95% CI 3.8%–10.7%). There were no significant changes to ED durations during nurse strikes (-1.7%, 95% CI -1.5% to 4.7%). Changes in emergency inpatient occupancy explained a proportion of the change in average ED durations (resident doctor 10.4%, consultants 53.3%, combined doctors 5.4% and paramedics 14.3%). The impact of strikes on ED attendance volumes was mixed. The net effect of these changes explained 1.5%, 16.8% and 28.8% of the change in average ED durations observed during residents, combined doctor and paramedic strikes, respectively. During the residents’ strikes, patients were more likely to receive treatments in ED (adjusted incident risk ratio 1.013, 95% CI 1.008–1.018), but less likely to be admitted (adjusted odds ratio 0.963, 95% CI 0.946–0.980). Efforts to meet the 4-h target intensified during the resident, consultant and combined doctors strike, but reduced during the nurse and paramedic strikes. This explained 2.7% and 17.1% of the changes in average ED durations observed during the resident and consultant strikes, respectively. There were substantial reductions in many forms of planned hospital care during the resident, consultant and combined doctor strikes, but these did not contribute to the observed reductions in ED durations. Conclusion: Industrial action – particularly by resident and consultant doctors – was associated with shorter ED stays, partly mediated by greater emergency bed availability, lower demand and intensified throughput efforts. However, much of the reduction during resident strikes remained unexplained, suggesting unmeasured operational or behavioural adaptations. Substantial reductions in planned care did not significantly affect ED performance.
- 1 July 2026
- Published by SAGE Publications in Journal of the Royal Society of Medicine
- Vol. 119 (7) , 190-204
Open AccessIndustrial action and emergency department attendances in England, 2022–2024: a retrospective multicentre causal mediation analysis
Objectives: Between December 2022 and July 2024, the English National Health Service (NHS) experienced 27 periods of industrial action spanning 78 days, involving hospital and ambulance staff. We examined the direct and indirect impacts of these strikes on emergency department (ED) performance Design: A retrospective causal mediation analysis. Effects were estimated using mixed effects accelerated failure time, linear and generalised linear regression models with patient- and hospital-level covariates within a causal mediation framework. Setting: 20 major (Type 1) EDs in England with high-quality linkage across ED, inpatient, and imaging data. Participants: Patients attending these EDs between August 2022 and July 2024. Main outcome measures: A patient’s time in ED analysed in relation to strike activity at the mid-point of attendance by one or more staff groups: (1) resident/junior doctors, (2) consultants, (3) both resident and consultant doctors, (4) paramedics and (5) nurses. Results: Average duration of ED attendances reduced on days affected by residents’ strikes (-12.6%, 95% CI -10.4% to -14.8%), consultant strikes (-5.6%, 95% CI -2.7% to -8.4%), paramedic strikes (-4.5%, 95% CI -2.0% to -6.8%), but increased when residents and consultants were on strike simultaneously (+7.2%, 95% CI 3.8%–10.7%). There were no significant changes to ED durations during nurse strikes (-1.7%, 95% CI -1.5% to 4.7%). Changes in emergency inpatient occupancy explained a proportion of the change in average ED durations (resident doctor 10.4%, consultants 53.3%, combined doctors 5.4% and paramedics 14.3%). The impact of strikes on ED attendance volumes was mixed. The net effect of these changes explained 1.5%, 16.8% and 28.8% of the change in average ED durations observed during residents, combined doctor and paramedic strikes, respectively. During the residents’ strikes, patients were more likely to receive treatments in ED (adjusted incident risk ratio 1.013, 95% CI 1.008–1.018), but less likely to be admitted (adjusted odds ratio 0.963, 95% CI 0.946–0.980). Efforts to meet the 4-h target intensified during the resident, consultant and combined doctors strike, but reduced during the nurse and paramedic strikes. This explained 2.7% and 17.1% of the changes in average ED durations observed during the resident and consultant strikes, respectively. There were substantial reductions in many forms of planned hospital care during the resident, consultant and combined doctor strikes, but these did not contribute to the observed reductions in ED durations. Conclusion: Industrial action – particularly by resident and consultant doctors – was associated with shorter ED stays, partly mediated by greater emergency bed availability, lower demand and intensified throughput efforts. However, much of the reduction during resident strikes remained unexplained, suggesting unmeasured operational or behavioural adaptations. Substantial reductions in planned care did not significantly affect ED performance.
- Open Access
Assessing the efficacy of human mesenchymal stromal cells of different tissue origins in a mouse model of kidney ischaemia reperfusion injury
Rodent models of kidney disease have been widely used to assess the efficacy, safety and mode of action of mesenchymal stromal cells (MSCs) as therapies. However, because kidney disease models, MSC type and the methods used to assess kidney injury tend to differ between research groups, it is difficult to obtain data that are sufficiently robust and reproducible to support clinical translation. We present here for the first time a side-by-side analysis of the performance of human MSCs derived from the most commonly used tissue sources, bone marrow (BM-), adipose- (A-) and umbilical cord (UC-), in a kidney ischaemia reperfusion injury (IRI) model in mice. For each animal, we performed a comprehensive assessment of kidney function and health by longitudinal transdermal measurements of sinistrin clearance, serum biomarker levels at the experimental endpoint, and histopathological scoring of sections from left and right kidneys. Furthermore, we tracked the MSCs by bioluminescence imaging in the injured mice to determine their viability over time and their capacity for homing to the damaged kidneys. Our results reveal that only modest if any beneficial effects of the MSC treatments were detectable on kidney function and histology, irrespective of cell type administered. Furthermore, all three MSC types were sequestered in the lungs without reaching the kidneys, and had completely disappeared within 7 days. Our data suggest that none of the MSC types has the capability to improve renal health following IRI to a meaningful extent, questioning their suitability as a clinical therapy.
Open AccessAssessing the efficacy of human mesenchymal stromal cells of different tissue origins in a mouse model of kidney ischaemia reperfusion injury
Rodent models of kidney disease have been widely used to assess the efficacy, safety and mode of action of mesenchymal stromal cells (MSCs) as therapies. However, because kidney disease models, MSC type and the methods used to assess kidney injury tend to differ between research groups, it is difficult to obtain data that are sufficiently robust and reproducible to support clinical translation. We present here for the first time a side-by-side analysis of the performance of human MSCs derived from the most commonly used tissue sources, bone marrow (BM-), adipose- (A-) and umbilical cord (UC-), in a kidney ischaemia reperfusion injury (IRI) model in mice. For each animal, we performed a comprehensive assessment of kidney function and health by longitudinal transdermal measurements of sinistrin clearance, serum biomarker levels at the experimental endpoint, and histopathological scoring of sections from left and right kidneys. Furthermore, we tracked the MSCs by bioluminescence imaging in the injured mice to determine their viability over time and their capacity for homing to the damaged kidneys. Our results reveal that only modest if any beneficial effects of the MSC treatments were detectable on kidney function and histology, irrespective of cell type administered. Furthermore, all three MSC types were sequestered in the lungs without reaching the kidneys, and had completely disappeared within 7 days. Our data suggest that none of the MSC types has the capability to improve renal health following IRI to a meaningful extent, questioning their suitability as a clinical therapy.
- Open Access
- 26 April 2026
- Published by Elsevier in SSRN Electronic Journal
Data-Driven Framework to Maximise the Value of Testing in Epidemic Contexts
Testing is a cornerstone of epidemic response, underpinning public health and social measures, clinical care, and surveillance. However, testing interventions are inherently complex – not only their implementation but also their effects. The value of testing in epidemics depends on managing this complexity with clear objectives, appropriate technologies, effective implementation, and timely adaptation to changing epidemiological and social contexts. Collectively, these factors determine whether testing delivers its intended benefit. We propose a data-driven framework to guide effective and equitable testing in epidemics. The framework is informed by an interdisciplinary expert consultation that reviewed community testing in response to SARS-CoV-2 in the UK, alongside international experiences. The framework has four components: defining purpose; selecting and evaluating technology; designing engagement and implementation; and enabling monitoring, evaluation, and optimisation. We outline inputs, outputs and required tools to support framework delivery. Preparing this capability in advance of emergencies should be central to pandemic preparedness.
- 26 April 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessData-Driven Framework to Maximise the Value of Testing in Epidemic Contexts
Testing is a cornerstone of epidemic response, underpinning public health and social measures, clinical care, and surveillance. However, testing interventions are inherently complex – not only their implementation but also their effects. The value of testing in epidemics depends on managing this complexity with clear objectives, appropriate technologies, effective implementation, and timely adaptation to changing epidemiological and social contexts. Collectively, these factors determine whether testing delivers its intended benefit. We propose a data-driven framework to guide effective and equitable testing in epidemics. The framework is informed by an interdisciplinary expert consultation that reviewed community testing in response to SARS-CoV-2 in the UK, alongside international experiences. The framework has four components: defining purpose; selecting and evaluating technology; designing engagement and implementation; and enabling monitoring, evaluation, and optimisation. We outline inputs, outputs and required tools to support framework delivery. Preparing this capability in advance of emergencies should be central to pandemic preparedness.
- Open Access
Gas Chromatography–Sensor System Aids Diagnosis of Inflammatory Bowel Disease, and Separates Crohn’s from Ulcerative Colitis, in Children
The diagnosis of inflammatory bowel disease (IBD) in children and the need to distinguish between subtypes (Crohn’s disease (CD) and ulcerative colitis (UC)) requires lengthy investigative and invasive procedures. Non-invasive, rapid, and cost-effective tests to support these diagnoses are needed. Faecal volatile organic compounds (VOCs) are distinctive in IBD. VOC profiles can be rapidly determined using a gas chromatography–sensor device (OdoReader©). In an inception-cohort of children presenting with suspected IBD, we directly compared the diagnostic fidelity of faecal calprotectin (FCP, a non-specific protein marker of intestinal inflammation) with OdoReader© VOC profiles of children subsequently diagnosed with IBD with matched controls diagnosed with other gastrointestinal conditions. The OdoReader© was 82% (95% confidence interval 75–89%) sensitive and 71% (61–80%) specific but did not outperform FCP (sensitivity 93% (77–99%) and specificity 86% (67–96%); 250 µg/g FCP cut off) in the diagnosis of IBD from other gastrointestinal conditions when validated in a separate sample from the same cohort. However, unlike FCP and better than other similar technologies, the OdoReader© could distinguish paediatric CD from UC (up to 88% (82–93%) sensitivity and 80% (71–89%) specificity in the validation set) and justifies further validation in larger studies. A non-invasive test based on VOCs could help streamline and limit invasive investigations in children.
Open AccessGas Chromatography–Sensor System Aids Diagnosis of Inflammatory Bowel Disease, and Separates Crohn’s from Ulcerative Colitis, in Children
The diagnosis of inflammatory bowel disease (IBD) in children and the need to distinguish between subtypes (Crohn’s disease (CD) and ulcerative colitis (UC)) requires lengthy investigative and invasive procedures. Non-invasive, rapid, and cost-effective tests to support these diagnoses are needed. Faecal volatile organic compounds (VOCs) are distinctive in IBD. VOC profiles can be rapidly determined using a gas chromatography–sensor device (OdoReader©). In an inception-cohort of children presenting with suspected IBD, we directly compared the diagnostic fidelity of faecal calprotectin (FCP, a non-specific protein marker of intestinal inflammation) with OdoReader© VOC profiles of children subsequently diagnosed with IBD with matched controls diagnosed with other gastrointestinal conditions. The OdoReader© was 82% (95% confidence interval 75–89%) sensitive and 71% (61–80%) specific but did not outperform FCP (sensitivity 93% (77–99%) and specificity 86% (67–96%); 250 µg/g FCP cut off) in the diagnosis of IBD from other gastrointestinal conditions when validated in a separate sample from the same cohort. However, unlike FCP and better than other similar technologies, the OdoReader© could distinguish paediatric CD from UC (up to 88% (82–93%) sensitivity and 80% (71–89%) specificity in the validation set) and justifies further validation in larger studies. A non-invasive test based on VOCs could help streamline and limit invasive investigations in children.
- Open Access
Can self-testing be enhanced to hasten safe return of healthcare workers in pandemics? Random order, open label trial using two manufacturers’ SARS-CoV-2 lateral flow devices concurrently
Objectives To inform management of competing risks from Covid-19 and key-worker absence, we evaluated whether using two manufacturers’ lateral flow tests (LFTs) concurrently improved SARS-CoV-2 Omicron detection and was acceptable to hospital staff. In a nested study, to understand the risks of return to work after a fixed number of days of isolation or quarantine, we examined virus culture at Days 5-7 after positive test or significant exposure. Methods and Analysis 1419 fully-vaccinated Liverpool (UK) University Hospitals staff participated in a random-order, open-label trial testing whether dual LFTs improved SARS-CoV2 detection, and whether dual swabbing was acceptable to users. Main outcome was self-reported LFT result. Staff enrolled via routine testing sites for symptomatic staff and close contacts. Recruitment took place between 7th February and 8th May 2022. Participants employed nose-throat swab Innova and nose-only swab Orient Gene LFTs for 10 days, with daily LFTs taken in random order. A swab for polymerase chain reaction (PCR) analysis was taken at Day-5 and, if positive, Day-10. A questionnaire on acceptability was administered on exit. Selected participants gave swabs for viral culture on Days 5-7; swabs were delivered and returned by courier. Cultures were considered positive if cytopathic effect was apparent or the SARs-COV2 N gene sub-genomic RNA was detected by sequencing. Results 226 individuals reported 1466 pairs of LFT results. Tests disagreed in 127 cases (8.7%). Orient Gene was more likely (78 cf. 49, P=0.03) to be positive. Orient Gene positive Innova negative result-pairs became more frequent over time (PConclusions Dual brand testing increased LFT detection of SARS-CoV-2 antigen by a small but meaningful margin and was acceptable to hospital workers. Viral cultures demonstrated that policies recommending safe return to work ∼5 days after Omicron infection/exposure were flawed. Key-workers should be prepared for dynamic self-testing protocols in future pandemics. Trial registration https://www.isrctn.com/ISRCTN47058442 (IRAS Project ID:311842) Omicron BA.1 and BA.2 waves caused large-scale healthcare worker absence in late 2021 – early 2022, risking patient safety from both Covid-19 and reduced care capacity Lateral flow tests (LFTs) reliably detected SARS-CoV-2 antigen, more so with Omicron than prior variants, identifying the most infectious individuals Self-testing with LFT SARS-CoV-2 rapid antigen tests reduced Covid-19 transmission, mitigating risks of return to work, including healthcare settings Dual c.f. single brand LFT testing increased SARS-CoV-2 antigen detection marginally, but more than can be explained by extending swabbing from nose-only to nose-throat NHS deployment of nose-only LFTs in response to compound pressures from Omicron, winter and pandemic burnout was safe and acceptable to most participating hospital staff Culturable virus was detected confidently in a fifth (and potentially in a further third) of LFT-positive hospital workers 5-7 days after their self-referral for testing, indicating substantial protracted infectiousness This study shows international Covid-19 policies for return to work after fixed periods (e.g. 5 days after positive test) were flawed: too little emphasis was placed on variation in infectivity between individuals Future pandemic preparedness needs to plan testing quality assurance unified across healthcare and community self-testing contexts, including continuous study of serial daily antigen, nucleic acid and culturable virus test results
Open AccessCan self-testing be enhanced to hasten safe return of healthcare workers in pandemics? Random order, open label trial using two manufacturers’ SARS-CoV-2 lateral flow devices concurrently
Objectives To inform management of competing risks from Covid-19 and key-worker absence, we evaluated whether using two manufacturers’ lateral flow tests (LFTs) concurrently improved SARS-CoV-2 Omicron detection and was acceptable to hospital staff. In a nested study, to understand the risks of return to work after a fixed number of days of isolation or quarantine, we examined virus culture at Days 5-7 after positive test or significant exposure. Methods and Analysis 1419 fully-vaccinated Liverpool (UK) University Hospitals staff participated in a random-order, open-label trial testing whether dual LFTs improved SARS-CoV2 detection, and whether dual swabbing was acceptable to users. Main outcome was self-reported LFT result. Staff enrolled via routine testing sites for symptomatic staff and close contacts. Recruitment took place between 7th February and 8th May 2022. Participants employed nose-throat swab Innova and nose-only swab Orient Gene LFTs for 10 days, with daily LFTs taken in random order. A swab for polymerase chain reaction (PCR) analysis was taken at Day-5 and, if positive, Day-10. A questionnaire on acceptability was administered on exit. Selected participants gave swabs for viral culture on Days 5-7; swabs were delivered and returned by courier. Cultures were considered positive if cytopathic effect was apparent or the SARs-COV2 N gene sub-genomic RNA was detected by sequencing. Results 226 individuals reported 1466 pairs of LFT results. Tests disagreed in 127 cases (8.7%). Orient Gene was more likely (78 cf. 49, P=0.03) to be positive. Orient Gene positive Innova negative result-pairs became more frequent over time (PConclusions Dual brand testing increased LFT detection of SARS-CoV-2 antigen by a small but meaningful margin and was acceptable to hospital workers. Viral cultures demonstrated that policies recommending safe return to work ∼5 days after Omicron infection/exposure were flawed. Key-workers should be prepared for dynamic self-testing protocols in future pandemics. Trial registration https://www.isrctn.com/ISRCTN47058442 (IRAS Project ID:311842) Omicron BA.1 and BA.2 waves caused large-scale healthcare worker absence in late 2021 – early 2022, risking patient safety from both Covid-19 and reduced care capacity Lateral flow tests (LFTs) reliably detected SARS-CoV-2 antigen, more so with Omicron than prior variants, identifying the most infectious individuals Self-testing with LFT SARS-CoV-2 rapid antigen tests reduced Covid-19 transmission, mitigating risks of return to work, including healthcare settings Dual c.f. single brand LFT testing increased SARS-CoV-2 antigen detection marginally, but more than can be explained by extending swabbing from nose-only to nose-throat NHS deployment of nose-only LFTs in response to compound pressures from Omicron, winter and pandemic burnout was safe and acceptable to most participating hospital staff Culturable virus was detected confidently in a fifth (and potentially in a further third) of LFT-positive hospital workers 5-7 days after their self-referral for testing, indicating substantial protracted infectiousness This study shows international Covid-19 policies for return to work after fixed periods (e.g. 5 days after positive test) were flawed: too little emphasis was placed on variation in infectivity between individuals Future pandemic preparedness needs to plan testing quality assurance unified across healthcare and community self-testing contexts, including continuous study of serial daily antigen, nucleic acid and culturable virus test results
- Open Access
- 1 October 2023
- Published by National Institute for Health and Care Research in Programme Grants for Applied Research
- Vol. 11 (6) , 1-72
Individualised variable-interval risk-based screening in diabetic retinopathy: the ISDR research programme including RCT
Background: Systematic annual screening for sight-threatening diabetic retinopathy is established in several countries but is resource intensive. Personalised (individualised) medicine offers the opportunity to extend screening intervals for people at low risk of progression and to target high-risk groups. However, significant concern exists among all stakeholders around the safety of changing programmes. Evidence to guide decisions is limited, with, to the best of our knowledge, no randomised controlled trials to date. Objectives: To develop an individualised approach to screening for sight-threatening diabetic retinopathy and test its acceptability, safety, efficacy and cost-effectiveness. To estimate the changing incidence of patient-centred outcomes. Design: A risk calculation engine; a randomised controlled trial, including a within-trial cost-effectiveness study; a qualitative acceptability study; and an observational epidemiological cohort study were developed. A patient and public group was involved in design and interpretation. Setting: A screening programme in an English health district of around 450,000 people. Participants: People with diabetes aged ≥ 12 years registered with primary care practices in Liverpool. Interventions: The risk calculation engine estimated each participant’s risk at each visit of progression to screen-positive diabetic retinopathy (individualised intervention group) and allocated their next appointment at 6, 12 or 24 months (high, medium or low risk, respectively). Main outcome measures: The randomised controlled trial primary outcome was attendance at first follow-up assessing the safety of individualised compared with usual screening. Secondary outcomes were overall attendance, rates of screen-positive and sight-threatening diabetic retinopathy, and measures of visual impairment. Cost-effectiveness outcomes were cost/quality-adjusted life year and incremental cost savings. Cohort study outcomes were rates of screen-positive diabetic retinopathy and sight-threatening diabetic retinopathy. Data sources: Local screening programme (retinopathy), primary care (demographic, clinical) and hospital outcomes. Methods: A seven-person patient and public involvement group was recruited. Data were linked into a purpose-built dynamic data warehouse. In the risk assessment, the risk calculation engine used patient-embedded covariate data, a continuous Markov model, 5-year historical local population data, and most recent individual demographic, retina and clinical data to predict risk of future progression to screen-positive. The randomised controlled trial was a masked, two-arm, parallel assignment, equivalence randomised controlled trial, with an independent trials unit and 1 : 1 allocation to individualised screening (6, 12 or 24 months, determined by risk calculation engine at each visit) or annual screening (control). Cost-effectiveness was assessed using a within-trial analysis over a 2-year time horizon, including NHS and societal perspectives and costs directly observed within the randomised controlled trial. Acceptability was assessed by purposive sampling of 60 people with diabetes and 21 healthcare professionals with semistructured interviews analysed thematically; this was a constant comparative method until saturation. The cohort was an 11-year retrospective/prospective screening population data set. Results: In the randomised controlled trial, 4534 participants were randomised: 2097 out of 2265 in the individualised arm (92.6%) and 2224 out of 2269 in the control arm (98.0%) remained after withdrawals. Attendance rates at first follow-up were equivalent (individualised 83.6%, control 84.7%) (difference –1.0%, 95% confidence interval –3.2% to 1.2%). Sight-threatening diabetic retinopathy detection rates were non-inferior: individualised 1.4%, control 1.7% (difference –0.3%, 95% confidence interval –1.1% to 0.5%). In the cost-effectiveness analysis, the mean differences in complete-case quality-adjusted life years (EuroQol-5 Dimensions, five-level version, and Health Utilities Index Mark 3) did not significantly differ from zero. Incremental cost savings per person not including treatment costs were from the NHS perspective £17.34 (confidence interval £17.02 to £17.67) and the societal perspective £23.11 (confidence interval £22.73 to £23.53). In the individualised arm, 43.2% fewer screening appointments were required. In terms of acceptability, changing to variable intervals was acceptable for the majority of people with diabetes and health-care professionals. Annual screening was perceived as unsustainable and an inefficient use of resources. Many people with diabetes and healthcare professionals expressed concerns that 2-year screening intervals may detect referable eye disease too late and might have a negative effect on perceptions about the importance of attendance and diabetes care. The 6-month interval was perceived positively. Among people with dementia, there was considerable misunderstanding about eye-related appointments and care. In the cohort study, the numbers of participants (total 28,384) rose over the 11 years (2006/7, n = 6637; 2016/17, n = 14,864). Annual incidences ranged as follows: screen-positive 4.4–10.6%, due to diabetic retinopathy 2.3–4.6% and sight-threatening diabetic retinopathy 1.3–2.2%. The proportions of screen-positive fell steadily but sight-threatening diabetic retinopathy rates remained stable. Limitations: Our findings apply to a single city-wide established English screening programme of mostly white people with diabetes. The cost-effectiveness analysis was over a short timeline for a long-standing disease; the study, however, was designed to test the safety and effectiveness of the screening regimen, not the cost-effectiveness of screening compared with no screening. Cohort data collection was partly retrospective: data were unavailable on people who had developed sight-threatening diabetic retinopathy or died prior to 2013. Conclusions: Our randomised controlled trial can reassure stakeholders involved in diabetes care that extended intervals and personalised screening is feasible, where data linkage is possible, and can be safely introduced in established screening programmes with potential cost savings compared with annual screening. Rates of screen-positive diabetic retinopathy and sight-threatening diabetic retinopathy are low and show consistent falls over time. Involvement of patients in research is crucial to success. Future work: Future work could include external validation with other programmes followed by scale-up of individualised screening outside a research setting and economic modelling beyond the 2-year time horizon. Trial registration: This trial is registered as ISRCTN87561257. Funding: This project was funded by the National Institute for Health and Care Research (NIHR) Programme Grants for Applied Research programme and will be published in full in Programme Grants for Applied Research; Vol. 11, No. 6. See the NIHR Journals Library website for further project information.
- 1 October 2023
- Published by National Institute for Health and Care Research in Programme Grants for Applied Research
- Vol. 11 (6) , 1-72
Open AccessIndividualised variable-interval risk-based screening in diabetic retinopathy: the ISDR research programme including RCT
Background: Systematic annual screening for sight-threatening diabetic retinopathy is established in several countries but is resource intensive. Personalised (individualised) medicine offers the opportunity to extend screening intervals for people at low risk of progression and to target high-risk groups. However, significant concern exists among all stakeholders around the safety of changing programmes. Evidence to guide decisions is limited, with, to the best of our knowledge, no randomised controlled trials to date. Objectives: To develop an individualised approach to screening for sight-threatening diabetic retinopathy and test its acceptability, safety, efficacy and cost-effectiveness. To estimate the changing incidence of patient-centred outcomes. Design: A risk calculation engine; a randomised controlled trial, including a within-trial cost-effectiveness study; a qualitative acceptability study; and an observational epidemiological cohort study were developed. A patient and public group was involved in design and interpretation. Setting: A screening programme in an English health district of around 450,000 people. Participants: People with diabetes aged ≥ 12 years registered with primary care practices in Liverpool. Interventions: The risk calculation engine estimated each participant’s risk at each visit of progression to screen-positive diabetic retinopathy (individualised intervention group) and allocated their next appointment at 6, 12 or 24 months (high, medium or low risk, respectively). Main outcome measures: The randomised controlled trial primary outcome was attendance at first follow-up assessing the safety of individualised compared with usual screening. Secondary outcomes were overall attendance, rates of screen-positive and sight-threatening diabetic retinopathy, and measures of visual impairment. Cost-effectiveness outcomes were cost/quality-adjusted life year and incremental cost savings. Cohort study outcomes were rates of screen-positive diabetic retinopathy and sight-threatening diabetic retinopathy. Data sources: Local screening programme (retinopathy), primary care (demographic, clinical) and hospital outcomes. Methods: A seven-person patient and public involvement group was recruited. Data were linked into a purpose-built dynamic data warehouse. In the risk assessment, the risk calculation engine used patient-embedded covariate data, a continuous Markov model, 5-year historical local population data, and most recent individual demographic, retina and clinical data to predict risk of future progression to screen-positive. The randomised controlled trial was a masked, two-arm, parallel assignment, equivalence randomised controlled trial, with an independent trials unit and 1 : 1 allocation to individualised screening (6, 12 or 24 months, determined by risk calculation engine at each visit) or annual screening (control). Cost-effectiveness was assessed using a within-trial analysis over a 2-year time horizon, including NHS and societal perspectives and costs directly observed within the randomised controlled trial. Acceptability was assessed by purposive sampling of 60 people with diabetes and 21 healthcare professionals with semistructured interviews analysed thematically; this was a constant comparative method until saturation. The cohort was an 11-year retrospective/prospective screening population data set. Results: In the randomised controlled trial, 4534 participants were randomised: 2097 out of 2265 in the individualised arm (92.6%) and 2224 out of 2269 in the control arm (98.0%) remained after withdrawals. Attendance rates at first follow-up were equivalent (individualised 83.6%, control 84.7%) (difference –1.0%, 95% confidence interval –3.2% to 1.2%). Sight-threatening diabetic retinopathy detection rates were non-inferior: individualised 1.4%, control 1.7% (difference –0.3%, 95% confidence interval –1.1% to 0.5%). In the cost-effectiveness analysis, the mean differences in complete-case quality-adjusted life years (EuroQol-5 Dimensions, five-level version, and Health Utilities Index Mark 3) did not significantly differ from zero. Incremental cost savings per person not including treatment costs were from the NHS perspective £17.34 (confidence interval £17.02 to £17.67) and the societal perspective £23.11 (confidence interval £22.73 to £23.53). In the individualised arm, 43.2% fewer screening appointments were required. In terms of acceptability, changing to variable intervals was acceptable for the majority of people with diabetes and health-care professionals. Annual screening was perceived as unsustainable and an inefficient use of resources. Many people with diabetes and healthcare professionals expressed concerns that 2-year screening intervals may detect referable eye disease too late and might have a negative effect on perceptions about the importance of attendance and diabetes care. The 6-month interval was perceived positively. Among people with dementia, there was considerable misunderstanding about eye-related appointments and care. In the cohort study, the numbers of participants (total 28,384) rose over the 11 years (2006/7, n = 6637; 2016/17, n = 14,864). Annual incidences ranged as follows: screen-positive 4.4–10.6%, due to diabetic retinopathy 2.3–4.6% and sight-threatening diabetic retinopathy 1.3–2.2%. The proportions of screen-positive fell steadily but sight-threatening diabetic retinopathy rates remained stable. Limitations: Our findings apply to a single city-wide established English screening programme of mostly white people with diabetes. The cost-effectiveness analysis was over a short timeline for a long-standing disease; the study, however, was designed to test the safety and effectiveness of the screening regimen, not the cost-effectiveness of screening compared with no screening. Cohort data collection was partly retrospective: data were unavailable on people who had developed sight-threatening diabetic retinopathy or died prior to 2013. Conclusions: Our randomised controlled trial can reassure stakeholders involved in diabetes care that extended intervals and personalised screening is feasible, where data linkage is possible, and can be safely introduced in established screening programmes with potential cost savings compared with annual screening. Rates of screen-positive diabetic retinopathy and sight-threatening diabetic retinopathy are low and show consistent falls over time. Involvement of patients in research is crucial to success. Future work: Future work could include external validation with other programmes followed by scale-up of individualised screening outside a research setting and economic modelling beyond the 2-year time horizon. Trial registration: This trial is registered as ISRCTN87561257. Funding: This project was funded by the National Institute for Health and Care Research (NIHR) Programme Grants for Applied Research programme and will be published in full in Programme Grants for Applied Research; Vol. 11, No. 6. See the NIHR Journals Library website for further project information.
- Open Access
Neurodevelopment of babies born to mothers with epilepsy: A prospective observational cohort study
Objective: Despite widespread monotherapy use of lamotrigine or levetiracetam during pregnancy, prospectively collected, blinded child development data are still limited. The NaME (Neurodevelopment of Babies Born to Mothers With Epilepsy) Study prospectively recruited a new cohort of women with epilepsy and their offspring for longitudinal follow‐up.Methods: Pregnant women of n = 401) were recruited from 21 hospitals in the UK. Data collection occurred during pregnancy (recruitment, trimester 3) and at 12 and 24 months of age. The primary outcome was blinded assessment of infant cognitive, language, and motor development on the Bayley Scales of Infant and Toddler Development (3rd edition) at 24 months of age with supplementary parent reporting on the Vinelands Adaptive Behavior Scales (2nd edition).Results: There were 394 live births, with 277 children (70%) completing the Bayley assessment at 24 months. There was no evidence of an association of prenatal exposure to monotherapy lamotrigine (−.74, SE = 2.9, 95% confidence interval [CI] = −6.5 to 5.0, p = .80) or levetiracetam (−1.57, SE = 3.1, 95% CI = −4.6 to 7.7, p = .62) with poorer infant cognition, following adjustment for other maternal and child factors in comparison to nonexposed children. Similar results were observed for language and motor scores. There was no evidence of an association between increasing doses of either lamotrigine or levetiracetam. Nor was there evidence that higher dose folic acid supplementation (≥5 mg/day) or convulsive seizure exposure was associated with child development scores. Continued infant exposure to antiseizure medications through breast milk was not associated with poorer outcomes, but the number of women breastfeeding beyond 3 months was low.Significance: These data are reassuring for infant development following in utero exposure to monotherapy lamotrigine or levetiracetam, but child development is dynamic, and future follow‐up is required to rule out later emerging effects.
Open AccessNeurodevelopment of babies born to mothers with epilepsy: A prospective observational cohort study
Objective: Despite widespread monotherapy use of lamotrigine or levetiracetam during pregnancy, prospectively collected, blinded child development data are still limited. The NaME (Neurodevelopment of Babies Born to Mothers With Epilepsy) Study prospectively recruited a new cohort of women with epilepsy and their offspring for longitudinal follow‐up.Methods: Pregnant women of n = 401) were recruited from 21 hospitals in the UK. Data collection occurred during pregnancy (recruitment, trimester 3) and at 12 and 24 months of age. The primary outcome was blinded assessment of infant cognitive, language, and motor development on the Bayley Scales of Infant and Toddler Development (3rd edition) at 24 months of age with supplementary parent reporting on the Vinelands Adaptive Behavior Scales (2nd edition).Results: There were 394 live births, with 277 children (70%) completing the Bayley assessment at 24 months. There was no evidence of an association of prenatal exposure to monotherapy lamotrigine (−.74, SE = 2.9, 95% confidence interval [CI] = −6.5 to 5.0, p = .80) or levetiracetam (−1.57, SE = 3.1, 95% CI = −4.6 to 7.7, p = .62) with poorer infant cognition, following adjustment for other maternal and child factors in comparison to nonexposed children. Similar results were observed for language and motor scores. There was no evidence of an association between increasing doses of either lamotrigine or levetiracetam. Nor was there evidence that higher dose folic acid supplementation (≥5 mg/day) or convulsive seizure exposure was associated with child development scores. Continued infant exposure to antiseizure medications through breast milk was not associated with poorer outcomes, but the number of women breastfeeding beyond 3 months was low.Significance: These data are reassuring for infant development following in utero exposure to monotherapy lamotrigine or levetiracetam, but child development is dynamic, and future follow‐up is required to rule out later emerging effects.
- Open Access
- 1 July 2022
- Published by Elsevier in eClinicalMedicine
- Vol. 50, 101519
Daily testing of contacts of SARS-CoV-2 infected cases as an alternative to quarantine for key workers in Liverpool: A prospective cohort study
- 1 July 2022
- Published by Elsevier in eClinicalMedicine
- Vol. 50, 101519
Open AccessDaily testing of contacts of SARS-CoV-2 infected cases as an alternative to quarantine for key workers in Liverpool: A prospective cohort study
- Open Access
- 4 February 2022
- Published by Oxford University Press (OUP) in Journal of Public Health
- Vol. 45 (1) , e38-e47
Rapid antigen testing in COVID-19 management for school-aged children: an observational study in Cheshire and Merseyside, UK
Background: Twice weekly lateral flow tests (LFTs) for secondary school children was UK Government policy from 8 March 2021. We evaluate use of LFTs (both supervised at test centres, and home test kits) in school-aged children in Cheshire and Merseyside.Methods: We report (i) number of LFT positives (ii) proportion of LFT positive with confirmatory reverse transcription polymerase chain reaction (PCR) test within 2 days, and (iii) agreement between LFT-positive and confirmatory PCR, and dependence of (i–iii) on COVID-19 prevalence.Findings: 1 248 468 LFTs were taken by 211 255 12–18 years old, and 163 914 by 52 116 5–11 years old between 6 November 2020 and 31 July 2021. Five thousand three hundred and fourteen (2.5%) 12–18 years old and 1996 (3.8%) 5–11 years old returned LFT positives, with 3829 (72.1%) and 1535 (76.9%) confirmatory PCRs, and 3357 (87.7%) and 1383 (90.1%) confirmatory PCR-positives, respectively.Monthly proportions of LFT positive with PCR negative varied between 4.7% and 35.3% in 12–18 years old (corresponding proportion of all tests positive: 9.7% and 0.3%).Deprivation and non-White ethnicity were associated with reduced uptake of confirmatory PCR.Interpretation: Substantial inequalities in confirmatory testing need more attention to avoid further disadvantage through education loss. When prevalence is low additional measures, including confirmatory testing, are needed. Local Directors of Public Health taking more control over schools testing may be needed.Funding: DHSC, MRC, NIHR, EPSRC.
- 4 February 2022
- Published by Oxford University Press (OUP) in Journal of Public Health
- Vol. 45 (1) , e38-e47
Open AccessRapid antigen testing in COVID-19 management for school-aged children: an observational study in Cheshire and Merseyside, UK
Background: Twice weekly lateral flow tests (LFTs) for secondary school children was UK Government policy from 8 March 2021. We evaluate use of LFTs (both supervised at test centres, and home test kits) in school-aged children in Cheshire and Merseyside.Methods: We report (i) number of LFT positives (ii) proportion of LFT positive with confirmatory reverse transcription polymerase chain reaction (PCR) test within 2 days, and (iii) agreement between LFT-positive and confirmatory PCR, and dependence of (i–iii) on COVID-19 prevalence.Findings: 1 248 468 LFTs were taken by 211 255 12–18 years old, and 163 914 by 52 116 5–11 years old between 6 November 2020 and 31 July 2021. Five thousand three hundred and fourteen (2.5%) 12–18 years old and 1996 (3.8%) 5–11 years old returned LFT positives, with 3829 (72.1%) and 1535 (76.9%) confirmatory PCRs, and 3357 (87.7%) and 1383 (90.1%) confirmatory PCR-positives, respectively.Monthly proportions of LFT positive with PCR negative varied between 4.7% and 35.3% in 12–18 years old (corresponding proportion of all tests positive: 9.7% and 0.3%).Deprivation and non-White ethnicity were associated with reduced uptake of confirmatory PCR.Interpretation: Substantial inequalities in confirmatory testing need more attention to avoid further disadvantage through education loss. When prevalence is low additional measures, including confirmatory testing, are needed. Local Directors of Public Health taking more control over schools testing may be needed.Funding: DHSC, MRC, NIHR, EPSRC.